Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. 

 Financial ResultsNet cash used in operating activities for the Year

$3.9 millionCash position at the end of the Year

$5.1 millionReported loss

$4.1 million 

Operational HighlightsCAVATAK™ Phase II CALM Melanoma Clinical Trial (USA) Highlights include:

  • CAVATAK™ presented at the American Society of Clinical Oncologists conference in June 2013 and the World Melanoma Congress in July 2013 to a global oncology audience.
  • Key milestone achieved with enrolment of the 35th patient. Independent Data Monitoring Committee reported that CAVATAK™ had met safety and tolerability criteria.
  • Patient enrolment now at 10 prestigious US cancer clinics, with acceleration since early 2013. Aiming for full recruitment by the end of the calendar year.
  • 23 patients have reached assessment point against the trial's primary endpoint of immune related Progression Free Survival (irPFS) at 6 months. Interim results very promising with 8 of 23 patients having achieved the primary endpoint. Trial target is 10 of 54 evaluable patients achieving primary endpoint.
  • 2 complete and 6 partial tumour responses from 30 assessable patients. Anti-cancer activity demonstrated in non-injected (metastatic or secondary) as well as the injected tumours.
  • CAVATAK™ Phase I studies completed (Australia)

  • Intravenously administered CAVATAK™ well tolerated in late stage cancer patients.
  • Some evidence of tumour stabilization in intravenous study after only a single dose.
  • Sound basis for a multi-dose intravenous Phase 1 / 2 trial (our STORM study).
  • CAVATAK™ Preclinical studies completed (A
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
    (Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
    (Date:1/14/2014)... , Jan. 14, 2014 NineSigma , ... hold its Innovation Leadership Summit , May 14-16, ... Cleveland Ohio . ... and organizations committed to breakthrough achievements through open innovation. ...
    Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
    ... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
    ... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
    Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
    (Date:4/23/2014)... from Sub-Saharan Africa, Latin America and Caribbean islands ... new research from St. Michael,s Hospital. , The ... of Obstetrics and Gynaecology , assessed the differences ... native-born women in six high-immigration countries Australia ... Valencia) and the United States (California, New Jersey ...
    (Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
    (Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
    (Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
    (Date:4/23/2014)... new computer program could help doctors predict which patients ... treatment. , The program, which assesses brain scans ... airport security and passport control, has been developed by ... study funded by the Wellcome Trust, which used the ... . , Stroke affects over 15 million people ...
    Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
    ... ... every year, 35 to 50 million Americans become infected with the flu (influenza). On average, ... Plano, TX is taking steps to combat these preventable deaths by offering free flu shots ... Plano, TX (Vocus) September 12, ...
    ... , , , ... important safety notice to its more than 750,000 subscribers of its ... wearing a "pendant" style help button. The service is used primarily ... at risk of falls. By pressing a "help button" worn on ...
    ... of Public Health has been awarded $18.4 million by ... U.S. Department of Defense to establish an Extremity Trauma ... the coordinating center for the Consortium that includes a ... with several major military treatment centers and the U.S. ...
    ... ... on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- PAINWeek® 2009, the national conference ... drug reform in the United States as keynote speaker former Assistant US Attorney Jennifer Bolen, ...
    ... help predict who,s susceptible to the disease, study says , ... to a higher risk of Alzheimer,s disease seems to affect ... thought, new research suggests. , The brains of people in ... -- which boosts the risk of Alzheimer,s but doesn,t guarantee ...
    ... , NEW YORK, Sept. 11 Duane Reade Holdings ... that, as the Local Presenting Sponsor of the 2009 Komen New ... its foundation, The Duane Reade Charitable Foundation, have raised $330,000 to ... to find a cure. This marks the third year that Duane ...
    Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Lifeline Issues Safety Notice to Subscribers 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Alzheimer's Gene Affects Brains of Young Adults 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3
    ... of Hemoglobin S in patient samples. Each ... and 20l of anticoagulated whole blood or ... test kit contains two bottles of phosphate ... and two vials of Sodium Hydrosulfite reagent ...
    ... CD-Chex Plus BC is an assayed control ... systems. CD-Chex Plus BC determines the accuracy ... in the process of immunophenotyping, including red ... subsets of leukocytes include: T lymphocytes, B ...
    Streck-T-Pack is specially designed for use on Coulter® Counter T Series instruments. Each convenient pack includes diluent, lysing agent and enzymatic cleanser. The shelf life is 18 months from ...
    ... CD-Chex CD34 is a ... leukocytes which can be used ... when evaluating CD34 positive cells. ... ISHAGE and ProCOUNT gating strategies. ...
    Medicine Products: